## UNITED STATES SECURITIES AND EXCHANGE COMMISSION June 5, 2018

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Neurocrine Biosciences, Inc.

File No. 0-22705 - CF#36415

Neurocrine Biosciences, Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to Forms 10-Q filed on July 29, 2010 and October 31, 2011.

Based on representations by Neurocrine Biosciences, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.2 to Form 10-Q filed July 29, 2010 through July 29, 2021 Exhibit 10.2 to Form 10-Q filed October 31, 2011 through July 29, 2021

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary